MDT shares have been almost flat so far this year, fluctuating between $82 and $93. In the trailing 52 weeks, the stock has returned a lackluster 2.3% growth.
The fourth quarter results come at a time when the medical device maker is embroiled in allegations that some of its pacemakers run out of charge without giving a warning to the patients, causing medical emergencies.
Earlier this month, the US Food and Drug Administration raised an alarm on pacemaker models Azure, Astra, Percepta, Serena and Solara for pre-mature battery depletion, though a recall wasn’t ordered. Two weeks later, a similar panel in India echoed the same concerns over Medtronic devices.
The management is likely to speak in detail about the issue as they go live during the earnings conference call.
READ:
WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS
In Q4, investors will be looking at the growth of its cardiac
and vascular group, as well as the diabetes unit, both of which are projected
to drive long-term traffic for the company.
Of late, Medtronic has been trying to diversify its portfolio
to offset weakness in certain areas of medical devices. The most recent move in
this regard was the acquisition of Titan Spine, a company that makes titanium
spine interbody implant.
This deal was announced last week.
In the last reported quarter, Medtronic topped consensus estimates on revenue and earnings for the and raised its earnings guidance for the fiscal year 2019. Shares were up 0.79% in premarket hours on Tuesday.
Worldwide revenues totaled $7.5 billion, up 2.4% from the same period last year. On an organic basis, revenues grew 4.4%. Adjusted net income rose 10% to $1.75 billion, or $1.29 per share.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.